The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

[1]  V. Ehemann,et al.  Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines. , 2009, Endocrine-related cancer.

[2]  M. Cazzaniga,et al.  Is it Time to Test Metformin in Breast Cancer Clinical Trials? , 2009, Cancer Epidemiology Biomarkers & Prevention.

[3]  V. Beral,et al.  Diabetes and modifiable risk factors for cardiovascular disease: the prospective Million Women Study , 2008, European Journal of Epidemiology.

[4]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[5]  D. Margolis,et al.  Association between serious ischemic cardiac outcomes and medications used to treat diabetes , 2008, Pharmacoepidemiology and drug safety.

[6]  F. McAlister,et al.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review , 2007, BMJ : British Medical Journal.

[7]  Alicja Wolk,et al.  Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.

[8]  E. Giovannucci,et al.  The role of obesity and related metabolic disturbances in cancers of the colon, prostate, and pancreas. , 2007, Gastroenterology.

[9]  W. Bilker,et al.  Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research , 2007, Pharmacoepidemiology and drug safety.

[10]  D. Leroith,et al.  The role of the IGF system in cancer growth and metastasis: overview and recent insights. , 2007, Endocrine reviews.

[11]  Nahum Sonenberg,et al.  Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.

[12]  S. Soedamah-Muthu,et al.  Mortality in people with Type 2 diabetes in the UK , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[13]  S. Majumdar,et al.  Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.

[14]  S. Larsson,et al.  Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[15]  Dario R Alessi,et al.  Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.

[16]  J. Lewis,et al.  Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. , 2004, Gastroenterology.

[17]  M. Thun,et al.  Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.

[18]  N. Day,et al.  Preliminary communication: glycated hemoglobin, diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European prospective investigation into cancer-Norfolk study. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[19]  S. Bonovas,et al.  Diabetes mellitus and risk of prostate cancer: a meta-analysis , 2004, Diabetologia.

[20]  L. Schäffer,et al.  Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. , 2000, Diabetes.

[21]  T. Walley,et al.  The UK General Practice Research Database , 1997, The Lancet.

[22]  H Jick,et al.  Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. , 1991, BMJ.